Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Kant, Sam; Azar, Antoine; Geetha, Duvuru

Kant, Sam; Azar, Antoine; Geetha, Duvuru.

Kant S; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Azar A; Division of Allergy and Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Geetha D; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: gduvura@jhmi.edu.

Kidney Int ; 101(2): 414-415, 2022 02.

Article in English | MEDLINE | ID: covidwho-1594623

Subject(s)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; COVID-19; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy; Antibodies, Antineutrophil Cytoplasmic; Antibody Formation; COVID-19 Vaccines; Humans; Remission Induction; Rituximab/adverse effects; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Kidney Int Year: 2022 Document Type: Article Affiliation country: J.kint.2021.11.012

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google